PENUMBRA INC
PENNYSETrading Snapshot
- Day Range
- $317.21 β $322.05
- 52-Week Range
- $221.26 β $362.41
- Volume
- $2.13B
- Avg Volume
- $2.10B
- Shares Outstanding
- 39.3M
- Next Earnings
- Oct 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.40B
- Last Q Revenue
- $390M
- P/E Ratio
- 78.1
- P/S Ratio
- 8.3x
- EPS (TTM)
- $4.07
- Dividend Yield
- β
- Dilution (1yr)
- +0.3%
Why Investors Own PEN
- βHigh-growth profile β revenue up +2.4% YoY with expanding US Equity exposure.
- βHealthy economics β 64% gross margin and 7% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PENUMBRA INC
PENAbout PENUMBRA INC
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
PENUMBRA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift PEN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
PENUMBRA INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.